Literature DB >> 2537385

Treatment of intraductal carcinoma with limited surgery: long-term follow-up.

W J Gallagher1, F C Koerner, W C Wood.   

Abstract

Adequate therapy for ductal carcinoma in situ (DCIS) remains controversial. In spite of limited follow-up, recent studies advocate excision and postoperative radiotherapy as treatment. In an effort to provide long-term follow-up information, we evaluated retrospectively a group of 17 patients treated without mastectomy. Thirteen patients were treated with local excision, while four received excision and postoperative radiotherapy. Median follow-up is 100 months, with minimum follow-up 78 months. Five patients (29%) have recurred locally, at a median of 47 months following initial therapy. Three of the local recurrences were invasive carcinomas; two were DCIS. The patients recurring with invasive carcinoma progressed to disseminated disease and death, at a median of 131 months following their local recurrence. Of the eight patients followed for more than 9 years, four (50%) have recurred. Two patients have developed contralateral breast cancer, both treated by mastectomy. No recurrences have occurred in the group receiving radiotherapy. We conclude that long-term follow-up is required to accurately assess local recurrence rates in this disease, and that many recurrences will be invasive carcinomas. Since this lesion is virtually 100% curable by mastectomy, further analysis of long-term studies is warranted before recommending breast conservation to the majority of patients with DCIS.

Entities:  

Mesh:

Year:  1989        PMID: 2537385     DOI: 10.1200/JCO.1989.7.3.376

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  8 in total

Review 1.  Management of in situ and minimally invasive breast carcinoma.

Authors:  E R Frykberg; K I Bland
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

2.  Prognostic factors for local recurrence in breast conservation therapy: residual cancers after lumpectomy.

Authors:  T Fukutomi; H Yamamoto; T Nanasawa; M Itabashi; T Hirota
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

3.  Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer.

Authors:  J D Iglehart; B J Kerns; G Huper; J R Marks
Journal:  Breast Cancer Res Treat       Date:  1995-06       Impact factor: 4.872

Review 4.  The role of radiotherapy in the conservative treatment of ductal carcinoma in situ of the breast.

Authors:  Csaba Polgár; Zsuzsanna Kahán; Zsolt Orosz; Gabriella Gábor; Janaki Hadijev; Gábor Cserni; Janina Kulka; Nóra Jani; Zoltán Sulyok; György Lázár; Gábor Boross; Csaba Diczházi; Eva Szabó; Zsolt László; Zoltán Péntek; Tibor Major; János Fodor
Journal:  Pathol Oncol Res       Date:  2008-04-26       Impact factor: 3.201

5.  Prevalence of aneuploidy, overexpressed ER, and overexpressed EGFR in random breast aspirates of women at high and low risk for breast cancer.

Authors:  C J Fabian; C Zalles; S Kamel; B F Kimler; R McKittrick; A S Tranin; S Zeiger; W P Moore; R S Hassanein; C Simon
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 6.  Current management of ductal carcinoma in situ.

Authors:  A Barth; R J Brenner; A E Giuliano
Journal:  West J Med       Date:  1995-10

Review 7.  Clinical Trials for Ductal Carcinoma In Situ of the Breast.

Authors:  Michelle S Han; Seema A Khan
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-09-11       Impact factor: 2.673

8.  Risk of hematologic malignancies after breast ductal carcinoma in situ treatment with ionizing radiation.

Authors:  Kang Wang; Zhuyue Li; Xingxing Chen; Jianjun Zhang; Yongfu Xiong; Guochao Zhong; Yang Shi; Qing Li; Xiang Zhang; Hongyuan Li; Tingxiu Xiang; Theodoros Foukakis; Tomas Radivoyevitch; Guosheng Ren
Journal:  NPJ Breast Cancer       Date:  2021-03-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.